Shopping Cart 0
Cart Subtotal
USD 0

Amicus Therapeutics Inc (FOLD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Amicus Therapeutics Inc (Amicus Therapeutics) is a biotechnology company that focuses on the research, development and commercialization of small molecules drugs and orally administered drugs known as pharmacological chaperones for the treatment of rare and orphan diseases. The company's lead product, Migalastat HCl, a small molecule is used for the treatment of Fabry disease. The other development products in the pipeline include ATB200/AT2221 for the treatment of Pompe disease, Fabry disease, and other lysosomal storage disorders; Migalastat for other conditions; and enzyme replacement therapies for other rare diseases. It has presence in the US, the UK, Ireland, France, the Netherlands, Germany, Spain, Italy and Japan. Amicus Therapeutics is headquartered in Cranbury, New Jersey, the US.

Amicus Therapeutics Inc (FOLD)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Amicus Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Amicus Therapeutics Raises USD4.7 Million in Venture Financing 12

Scioderm Raises USD20 Million in Series B Venture Financing 13

Callidus Biopharma Raises USD 4.6 Million In Series A Financing 14

Scioderm Raises USD 16 Million In Series A Financing 15

Scioderm Raises USD1 Million in Venture Financing 16

Partnerships 17

Amicus Therapeutics Enters into Research and Development Agreement with Perelman School of Medicine at the University of Pennsylvania 17

Amicus Therapeutics Enters Into Co-Development Agreement With Biogen Idec 18

Licensing Agreements 19

Scioderm Plans To License Pharmaceuticals To Develop Topical Products 19

Equity Offering 20

Amicus Therapeutics Raises USD300 Million in Public Offering of Shares 20

Amicus Therapeutics Raises USD258.8 Million in Public Offering of Shares 22

Amicus Therapeutics Raises USD258.8 Million in Public Offering of Shares 24

Amicus Therapeutics Raises USD103.5 Million in Public Offering of Shares 26

Amicus Therapeutics Raises USD 40 Million in Public Offering 28

Amicus Therapeutics Completes Private Placement Of Securities For USD 15 Million 29

Amicus Therapeutics Files Registration Statement For Public Offering Of Securities For USD 145 Million 30

Amicus Therapeutics Raises USD18.6 Million in Private Placement of Shares 31

Amicus Therapeutics Completes Public Offering Of Common Stock For USD 65 Million 32

Debt Offering 34

Amicus Therapeutics Raises USD250 Million in Private Placement of 3% Notes Due 2023 34

Amicus Therapeutics Announces Public Offering Of Debt Securities For USD 25 Million 36

Acquisition 37

Amicus Therapeutics Acquires Celenex 37

Amicus Therapeutics Acquires MiaMed 38

Amicus Therapeutics Acquires Scioderm 39

Amicus Therapeutics Acquires Callidus Biopharma, Drug Discovery Company, For USD130 Million 41

Amicus Therapeutics Inc-Key Competitors 42

Amicus Therapeutics Inc-Key Employees 43

Amicus Therapeutics Inc-Locations And Subsidiaries 44

Head Office 44

Other Locations & Subsidiaries 44

Recent Developments 46

Strategy And Business Planning 46

Sep 24, 2018: Amicus Therapeutics to buy Celenex for USD 100m upfront 46

Financial Announcements 47

Nov 05, 2018: Amicus Therapeutics announces third quarter 2018 financial results and corporate updates 47

Aug 07, 2018: Amicus Therapeutics announces second quarter 2018 financial results and corporate updates 49

May 08, 2018: Amicus Therapeutics Announces First Quarter 2018 Financial Results and Corporate Updates 51

Feb 28, 2018: Amicus Therapeutics Announces Full-Year 2017 Financial Results and 2018 Corporate Updates 53

Nov 08, 2017: Amicus Therapeutics Announces Third Quarter 2017 Financial Results and Corporate Updates 55

Aug 07, 2017: Amicus Therapeutics Announces Second Quarter 2017 Financial Results and Corporate Updates 58

May 09, 2017: Amicus Therapeutics Announces First Quarter 2017 Financial Results and Corporate Updates 60

Mar 01, 2017: Amicus Therapeutics Announces Full-Year 2016 Financial Results and Corporate Updates 62

Jan 09, 2017: Amicus Therapeutics Provides Full-Year 2017 Strategic Outlook and Financial Guidance 64

Corporate Communications 66

Sep 11, 2018: Amicus Therapeutics appoints Lynn D. Bleil as Board Director 66

Jun 08, 2018: Amicus Therapeutics Appoints President and COO Bradley L. Campbell to Board of Directors 67

Product News 68

10/04/2017: Amicus Therapeutics Announces Additional Positive Data in Pompe Disease Phase 1/2 Study at World Muscle Society 68

09/10/2018: Amicus Therapeutics announces regulatory and clinical updates for AT-GAA in Pompe Disease 70

05/15/2017: Amicus Therapeutics Announces Positive Functional Data from Initial Patients in Pompe Phase 1/2 Study 71

02/07/2018: Amicus Therapeutics Announces Additional Positive Data in Pompe Disease Phase 1/2 Study at 14th Annual WORLDSymposium 73

01/22/2018: Amicus Therapeutics Announces Presentations and Posters at 14th Annual WORLDSymposium 2018 75

Product Approvals 77

Jun 26, 2018: Amicus Therapeutics Announces European Regulatory and Clinical Updates for AT-GAA in Pompe Disease 77

Sep 21, 2017: U.S. FDA Grants Orphan Drug Designation for ATB200/AT2221 for Pompe Disease 79

Clinical Trials 80

Feb 15, 2017: Amicus Therapeutics Presents Important New Scientific Findings and Preclinical Data for Pompe Program at WORLDSymposium 2017 80

Other Significant Developments 81

Feb 27, 2018: Amicus Therapeutics Launches Healing Beyond Disease Initiatives to Change People's Lives Living with Rare Diseases 81

Jan 08, 2018: Amicus Therapeutics Provides Full-Year 2018 Strategic Outlook and Financial Guidance 82

Appendix 84

Methodology 84

About GlobalData 84

Contact Us 84

Disclaimer 84


List Of Figure

List of Figures

Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Amicus Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Amicus Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Amicus Therapeutics Raises USD4.7 Million in Venture Financing 12

Scioderm Raises USD20 Million in Series B Venture Financing 13

Callidus Biopharma Raises USD 4.6 Million In Series A Financing 14

Scioderm Raises USD 16 Million In Series A Financing 15

Scioderm Raises USD1 Million in Venture Financing 16

Amicus Therapeutics Enters into Research and Development Agreement with Perelman School of Medicine at the University of Pennsylvania 17

Amicus Therapeutics Enters Into Co-Development Agreement With Biogen Idec 18

Scioderm Plans To License Pharmaceuticals To Develop Topical Products 19

Amicus Therapeutics Raises USD300 Million in Public Offering of Shares 20

Amicus Therapeutics Raises USD258.8 Million in Public Offering of Shares 22

Amicus Therapeutics Raises USD258.8 Million in Public Offering of Shares 24

Amicus Therapeutics Raises USD103.5 Million in Public Offering of Shares 26

Amicus Therapeutics Raises USD 40 Million in Public Offering 28

Amicus Therapeutics Completes Private Placement Of Securities For USD 15 Million 29

Amicus Therapeutics Files Registration Statement For Public Offering Of Securities For USD 145 Million 30

Amicus Therapeutics Raises USD18.6 Million in Private Placement of Shares 31

Amicus Therapeutics Completes Public Offering Of Common Stock For USD 65 Million 32

Amicus Therapeutics Raises USD250 Million in Private Placement of 3% Notes Due 2023 34

Amicus Therapeutics Announces Public Offering Of Debt Securities For USD 25 Million 36

Amicus Therapeutics Acquires Celenex 37

Amicus Therapeutics Acquires MiaMed 38

Amicus Therapeutics Acquires Scioderm 39

Amicus Therapeutics Acquires Callidus Biopharma, Drug Discovery Company, For USD130 Million 41

Amicus Therapeutics Inc, Key Competitors 42

Amicus Therapeutics Inc, Key Employees 43

Amicus Therapeutics Inc, Other Locations 44

Amicus Therapeutics Inc, Subsidiaries 44

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Amicus Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Amicus Therapeutics Inc (Amicus Therapeutics) is a biotechnology company that focuses on the research, development and commercialization of small molecules drugs and orally administered drugs known as pharmacological chaperones for the treatment of rare and orphan diseases. The company's lead product, Migalastat HCl, a small molecule is used for the treatment of Fabry disease. The other development products in the pipeline include ATB200/AT2221 for the treatment of Pompe disease, Fabry disease, and other lysosomal storage disorders; Migalastat for other conditions; and enzyme replacement therapies for other rare diseases. It has presence in the US, the UK, Ireland, France, the Netherlands, Germany, Spain, Italy and Japan. Amicus Therapeutics is headquartered in Cranbury, New Jersey, the US.

Amicus Therapeutics Inc (FOLD)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Amicus Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Amicus Therapeutics Raises USD4.7 Million in Venture Financing 12

Scioderm Raises USD20 Million in Series B Venture Financing 13

Callidus Biopharma Raises USD 4.6 Million In Series A Financing 14

Scioderm Raises USD 16 Million In Series A Financing 15

Scioderm Raises USD1 Million in Venture Financing 16

Partnerships 17

Amicus Therapeutics Enters into Research and Development Agreement with Perelman School of Medicine at the University of Pennsylvania 17

Amicus Therapeutics Enters Into Co-Development Agreement With Biogen Idec 18

Licensing Agreements 19

Scioderm Plans To License Pharmaceuticals To Develop Topical Products 19

Equity Offering 20

Amicus Therapeutics Raises USD300 Million in Public Offering of Shares 20

Amicus Therapeutics Raises USD258.8 Million in Public Offering of Shares 22

Amicus Therapeutics Raises USD258.8 Million in Public Offering of Shares 24

Amicus Therapeutics Raises USD103.5 Million in Public Offering of Shares 26

Amicus Therapeutics Raises USD 40 Million in Public Offering 28

Amicus Therapeutics Completes Private Placement Of Securities For USD 15 Million 29

Amicus Therapeutics Files Registration Statement For Public Offering Of Securities For USD 145 Million 30

Amicus Therapeutics Raises USD18.6 Million in Private Placement of Shares 31

Amicus Therapeutics Completes Public Offering Of Common Stock For USD 65 Million 32

Debt Offering 34

Amicus Therapeutics Raises USD250 Million in Private Placement of 3% Notes Due 2023 34

Amicus Therapeutics Announces Public Offering Of Debt Securities For USD 25 Million 36

Acquisition 37

Amicus Therapeutics Acquires Celenex 37

Amicus Therapeutics Acquires MiaMed 38

Amicus Therapeutics Acquires Scioderm 39

Amicus Therapeutics Acquires Callidus Biopharma, Drug Discovery Company, For USD130 Million 41

Amicus Therapeutics Inc-Key Competitors 42

Amicus Therapeutics Inc-Key Employees 43

Amicus Therapeutics Inc-Locations And Subsidiaries 44

Head Office 44

Other Locations & Subsidiaries 44

Recent Developments 46

Strategy And Business Planning 46

Sep 24, 2018: Amicus Therapeutics to buy Celenex for USD 100m upfront 46

Financial Announcements 47

Nov 05, 2018: Amicus Therapeutics announces third quarter 2018 financial results and corporate updates 47

Aug 07, 2018: Amicus Therapeutics announces second quarter 2018 financial results and corporate updates 49

May 08, 2018: Amicus Therapeutics Announces First Quarter 2018 Financial Results and Corporate Updates 51

Feb 28, 2018: Amicus Therapeutics Announces Full-Year 2017 Financial Results and 2018 Corporate Updates 53

Nov 08, 2017: Amicus Therapeutics Announces Third Quarter 2017 Financial Results and Corporate Updates 55

Aug 07, 2017: Amicus Therapeutics Announces Second Quarter 2017 Financial Results and Corporate Updates 58

May 09, 2017: Amicus Therapeutics Announces First Quarter 2017 Financial Results and Corporate Updates 60

Mar 01, 2017: Amicus Therapeutics Announces Full-Year 2016 Financial Results and Corporate Updates 62

Jan 09, 2017: Amicus Therapeutics Provides Full-Year 2017 Strategic Outlook and Financial Guidance 64

Corporate Communications 66

Sep 11, 2018: Amicus Therapeutics appoints Lynn D. Bleil as Board Director 66

Jun 08, 2018: Amicus Therapeutics Appoints President and COO Bradley L. Campbell to Board of Directors 67

Product News 68

10/04/2017: Amicus Therapeutics Announces Additional Positive Data in Pompe Disease Phase 1/2 Study at World Muscle Society 68

09/10/2018: Amicus Therapeutics announces regulatory and clinical updates for AT-GAA in Pompe Disease 70

05/15/2017: Amicus Therapeutics Announces Positive Functional Data from Initial Patients in Pompe Phase 1/2 Study 71

02/07/2018: Amicus Therapeutics Announces Additional Positive Data in Pompe Disease Phase 1/2 Study at 14th Annual WORLDSymposium 73

01/22/2018: Amicus Therapeutics Announces Presentations and Posters at 14th Annual WORLDSymposium 2018 75

Product Approvals 77

Jun 26, 2018: Amicus Therapeutics Announces European Regulatory and Clinical Updates for AT-GAA in Pompe Disease 77

Sep 21, 2017: U.S. FDA Grants Orphan Drug Designation for ATB200/AT2221 for Pompe Disease 79

Clinical Trials 80

Feb 15, 2017: Amicus Therapeutics Presents Important New Scientific Findings and Preclinical Data for Pompe Program at WORLDSymposium 2017 80

Other Significant Developments 81

Feb 27, 2018: Amicus Therapeutics Launches Healing Beyond Disease Initiatives to Change People's Lives Living with Rare Diseases 81

Jan 08, 2018: Amicus Therapeutics Provides Full-Year 2018 Strategic Outlook and Financial Guidance 82

Appendix 84

Methodology 84

About GlobalData 84

Contact Us 84

Disclaimer 84


List Of Figure

List of Figures

Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Amicus Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Amicus Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Amicus Therapeutics Raises USD4.7 Million in Venture Financing 12

Scioderm Raises USD20 Million in Series B Venture Financing 13

Callidus Biopharma Raises USD 4.6 Million In Series A Financing 14

Scioderm Raises USD 16 Million In Series A Financing 15

Scioderm Raises USD1 Million in Venture Financing 16

Amicus Therapeutics Enters into Research and Development Agreement with Perelman School of Medicine at the University of Pennsylvania 17

Amicus Therapeutics Enters Into Co-Development Agreement With Biogen Idec 18

Scioderm Plans To License Pharmaceuticals To Develop Topical Products 19

Amicus Therapeutics Raises USD300 Million in Public Offering of Shares 20

Amicus Therapeutics Raises USD258.8 Million in Public Offering of Shares 22

Amicus Therapeutics Raises USD258.8 Million in Public Offering of Shares 24

Amicus Therapeutics Raises USD103.5 Million in Public Offering of Shares 26

Amicus Therapeutics Raises USD 40 Million in Public Offering 28

Amicus Therapeutics Completes Private Placement Of Securities For USD 15 Million 29

Amicus Therapeutics Files Registration Statement For Public Offering Of Securities For USD 145 Million 30

Amicus Therapeutics Raises USD18.6 Million in Private Placement of Shares 31

Amicus Therapeutics Completes Public Offering Of Common Stock For USD 65 Million 32

Amicus Therapeutics Raises USD250 Million in Private Placement of 3% Notes Due 2023 34

Amicus Therapeutics Announces Public Offering Of Debt Securities For USD 25 Million 36

Amicus Therapeutics Acquires Celenex 37

Amicus Therapeutics Acquires MiaMed 38

Amicus Therapeutics Acquires Scioderm 39

Amicus Therapeutics Acquires Callidus Biopharma, Drug Discovery Company, For USD130 Million 41

Amicus Therapeutics Inc, Key Competitors 42

Amicus Therapeutics Inc, Key Employees 43

Amicus Therapeutics Inc, Other Locations 44

Amicus Therapeutics Inc, Subsidiaries 44

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Amicus Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.